An image uploaded to Strapi called project_scheibye-knudsen-lab_hero

IP-NFT

A VITADAO PROJECT

The Longevity Molecule - Scheibye-Knudsen Lab

INITIATED JUNE 23, 2021

What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.4 billion prescriptions to understand the impact of drugs on human lifespan.

Background

The study, consisting of over 1.4 billion prescriptions, found that a number of prescription drugs were highly associated with longer life- and health-span in long-live populations. Here, we present a unique investment opportunity. We seek to validate these observations through a series of carefully conducted wet lab experiments. If successful, this work could result in the repurposing of several FDA-approved therapeutics for the purpose of extending human lifespan, at a lower cost and over faster timelines than conceivably possible with de novo drug discovery. This unique investment opportunity allows savvy longevity investors the chance to own a share of the potential intellectual property generated from these studies, and in turn, a potential share in the future of life extension.

Aims, Hypothesis & Results

The global elderly population is projected to substantially increase throughout the 21st century. By the year 2100 a fifth of the total world population will be aged 65 or older, posing a serious socioeconomic challenge to societies world-wide. Interventions that ensure healthy aging are therefore of critical importance.

Timeline

The Scheibye-Knudsen Lab will test the identified drugs' ability to attenuate features of aging in a controlled laboratory setting. Here, the molecules will be tested in human cells and in the animal model drosophila melanogaster (fruit flies). Fruit flies are used extensively in biomedical research and particular aging research as they have a short lifespan of about 60 days.
Additionally, the drugs will be tested in human cells to rapidly understand how the molecules affect human cellular aging.

Pre-Clinical Studies 1: Testing in Fruit Flies and Human Cells
Required Funding: $500,000
Duration: 24 Months


VitaDAO Board Evaluation Writeup

This program focuses on testing and developing three of these small molecules as possible interventions in aging. Specifically, we will test the drugs on human cell cultures and in various animal models. Importantly, the current anti-aging market stands at 200 billion USD, even without a single scientifically proven treatment. Our molecules target this specific market with the aim of letting everyone live healthier, happier and longer lives.

FUNDING AMOUNT

$537,000

PROJECT TEAM

Morten Scheibye-Knudsen

Morten Scheibye-Knudsen

Research Lead

AT A GLANCE

Stage: Early Stage Preclinical Discovery

Area: Drug Repurposing

Status: Ongoing

Patent Status: Not Filed Yet

PROJECT Updates

MARCH 31, 2025

Manuscript in preparation

SEPTEMBER 20, 2023

Validated the lead drug series with independent studies

JUNE 30, 2023

Study completed: identified compounds with positive effects on cellular senescence.

AUGUST 17, 2021

5. Morten IP-NFT Transfer Ceremony with Molecule

JULY 29, 2021

4. AMA Scheibye-Knudsen Lab Funding Proposal

JUNE 23, 2021

Project Initiated

JUNE 15, 2021

3. Morten-Cell-Lab

APRIL 23, 2021

2. Lab-Tour with Research Lead Morten

APRIL 19, 2021

1. The Flies are ready!

APRIL 4, 2021

0. Intro to The Scheibye-Knudsen Lab